Comparative efficacy of fingolimod vs natalizumab A French multicenter observational study

Affiliation auteurs!!!! Error affiliation !!!!
TitreComparative efficacy of fingolimod vs natalizumab A French multicenter observational study
Type de publicationJournal Article
Year of Publication2016
AuteursBarbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, de Seze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanche J-P, Tourbah A, Stankoff B, Khedr AAl, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Creange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA, Grp CFSEP, Grp OFSEP
JournalNEUROLOGY
Volume86
Pagination771-778
Date PublishedFEB 23
Type of ArticleArticle
ISSN0028-3878
Résumé

{Objective: To compare natalizumab and fingolimod on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) from 27 multiple sclerosis centers participating in the French follow-up cohort Observatoire of Multiple Sclerosis. Methods: Patients with RRMS included in the study were aged from 18 to 65 years with an Expanded Disability Status Scale score of 0-5.5 and an available brain MRI performed within the year before treatment initiation. The data were collected for 326 patients treated with natalizumab and 303 with fingolimod. The statistical analysis was performed using 2 different methods: logistic regression and propensity scores (inverse probability treatment weighting). Results: The confounder-adjusted proportion of patients with at least one relapse within the first and second year of treatment was lower in natalizumab-treated patients compared to the fingolimod group (21.1% vs 30.4% at first year
DOI10.1212/WNL.0000000000002395